Skip to main content


Details of the Drug
Generic Name:
Drug Type:
Bispecific CD20-directed CD3 T-cell engager
How the Drug is Given:

Injection, for subcutaneous use


Indications and Usage

Epcoritamab-bysp is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy

Side effects needing medical attention

The most common adverse reactions are cytokine release syndrome (CRS), fatigue, musculoskeletal pain, injection site reactions, fever, abdominal pain, nausea, and diarrhea. The most common laboratory abnormalities are decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, decreased hemoglobin, and decreased platelets.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.